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INTRODUCTION
The transferrin receptor, a glycoprotein
present on the surface of most cells, is responsible
for binding transferrin during the endocytosis of
iron. The soluble form of the receptor (sTfR) was
initially described by Kohgo et al and is derived
from the cleavage of the extracellular portion of
the receptor.
1
 The expression of sTfR is regulated
by the availability of iron. Thus, an iron deficiency
rapidly induces synthesis of the receptor and an
excess of iron suppresses its synthesis.
1-3
 High
levels of sTfR have been reported in immune
hemolytic anemia, hereditary spherocytosis, Hb
H disease, β thalassemia intermedia and sickle
cell syndromes. The reported correlation between
the degree of hemolysis and sTfR levels supports
the hypothesis that the determination of sTfR
concentrations could be a useful indicator of the




 analyzed the clinical
significance of sTfR levels in patients with S
hemoglobinopathy and found that there was no
alteration in the serum concentrations of this
receptor during infectious situations or painful
crises. However, they observed high sTfR levels
in patients with hypersplenism, which returned
to normal values after splenectomy. These
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Objective: To correlate spleen function with soluble
transferrin receptor (sTfR) levels and red cell ferritin (RCF)
values in patients with sickle cell diseases.
Design: Prospective study.
Location: University Hospital, School of Medical Sciences,
State University of Campinas; a tertiary hospital.
Participants: 60 patients with sickle cell diseases, in a
steady state, who had not received blood transfusions for 3
months; 28 normal individuals with no clinical or
laboratory signs of anemia.
Measurements: Determination of serum iron, transferrin
iron-binding capacity, serum ferritin, RCF and sTfR. Evaluation
of spleen function: erythrocytes with pits were quantified.
Results: Patients with sickle cell anemia had sTfR levels
significantly higher than in normal individuals or those with
HbSC (p=0.0001) and there was an inverse correlation
between sTfR and fetal Hb (p=0.0016). RCF values were
significantly higher in sickle cell anemia patients than in
normal individuals or those with HbSC (p=0.0001), and there
was a correlation between RCF and pitted erythrocytes
(p=0.0512).
Conclusion: The association between sTfR and fetal Hb
confirms the contribution of fetal Hb to improving the
hemolytic state by minimizing the consequent reactive
erythrocyte expansion. High sTfR levels are not related to
the degree of spleen function deficiency seen in sickle cell
disease patients. The deficiency in the exocytosis process of
the spleen occurring in sickle cell anemia patients may
contribute to their accumulation of RCF.
Key words: Hemoglobinopathies. Pitted erythrocytes.
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Original Article
Sao Paulo Med J/Rev Paul Med 1999; 117(4):145-50.
146
Sao Paulo Med J/Rev Paul Med 1999; 117(4):145-50.
changes most likely reflect the extent of
erythrocyte expansion before and after
splenectomy. In individuals with sickle cell
disease, repeated infarctions resulting from
vascular occlusion by erythrocytes leads to
deficient functioning of the spleen, and hence,
to a greater susceptibility to infections.
7
 Deficient
functioning of the spleen may also be related to
high levels of red cell ferritin (RCF) in patients
with hemoglobinopathies, probably due a
deficiency in the exocytosis of excess ferritin, a
process which occurs preferentially in the spleen.
8
To investigate the relation between sTfR
levels and the degree of spleen function
deficiency, we have examined the correlation
between the serum concentrations of the sTfR and
the number of erythrocytes with membrane
irregularities (“pits”) in patients with S
hemoglobinopathy. Pitted erythrocytes are a well-
established indicator of spleen function.
9
METHODS
Patients. Sixty patients with sickle cell
diseases seen at the Hemocentro-Unicamp were
studied. Forty-three had sickle cell anemia (SS),
seven had Sβ thalassemia (Sβthal), nine had
hemoglobin SC disease and one was CC
homozygous (SC+CC group). All patients were
adults in a steady state and had not received a
blood transfusion for 3 months. They all gave
their informed consent to participate in this study
which was approved by the hospital Ethics
Committee. Twenty-eight normal individuals (N)
with no clinical or laboratory signs of anemia
served as the control for this study.
Hematological profile. The hematological
measurements were obtained using a Cobas
Argos (ABX - Horiba, France) analyzer. The levels
of fetal hemoglobin (HbF) were determined by
an alkaline denaturation method.
10
TABLE I - Iron status of the various groups studied
N SS SβThal† SC+CC
Parameters n mean SD n mean SD n mean SD n mean SD
SI 28 88.18 30,0 43 129.53* 59.0 7 137.14 59.4 10 105.7 27.85
(µg/dL) (38-155) (41-254) (75-253) (65-144)
TIBC 28 300.93 59.1 43 287.14 69.7 7 296.71 5.71 10 303.6 35.0
(µg/dL) (218-394) (174-454) (245-389) (242-364)
SF 28 63.23 46.9 43   608.95*1171.5 7 985.79 1249 10 291.1 385.7
(ng/ml) (11-162) (12-5870) (36-3020) (36-1280)
RCF 28 11.47 7.48 41   50.29* 45.9 7 54.76 37.1 10    18.78** 10.9
(att/cell) (3.22-35.3) (9.58-213.3) (8.7-128.4) (2.8-33.3)
sTfR 28 2.10 0.37 42   13.69* 5.23 5 13.04 3.95 9     6.58*/** 1.36
(µg/ml) (1.3-2.83) (2.54-29.44) (8.88-17.6) (4.76-8.08)
[(range)]
SI: serum iron; TIBC: transferrin iron binding capacity; SF: serum ferritin
RCF: red cell ferritin; sTfR: soluble transferrin receptor
* significantly different from N (p<0.05)
** significantly different from SS (p<0.05)
† no comparison made (n=7)
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Evaluation of the iron state. Determination
of serum iron (SI) and the transferrin iron-binding
capacity (TIBC) was done with a Mira Plus Cobas
analyzer (Roche - Switzerland) using Unimate 5
Iron and Unimate 7 UIBC kits (Roche Diagnostic
Systems - Switzerland). Serum ferritin (SF) was
determined by a fluorometric immunoenzymatic
test (Stratus-Dade International Inc. - Miami, USA)
and hemolyzed RCF levels were quantified by a




serum concentration of sTfR was measured by
an immunoenzymatic technique (Quantikine R&D
Systems - USA). The samples from SS and Sβthal
patients were diluted 1:400 prior to assaying.
All samples were kept at -80
0
C.
Evaluation of spleen function. Erythrocytes
with pits were quantified by interference contrast
microscopy.
12
Statistical methods. For comparison
between the groups, the Mann-Whitney or
Kruskal-Wallis tests were employed for variance
analysis and the Spearman correlation coefficient
test was used for assessing the association
between variables, with level of significance set
at <0.05.
RESULTS
Evaluation of the sTfR levels. The serum
concentrations of sTfR were statistically different
when the N and SS, N and SC+CC, and SS
and SC+CC groups were compared (p<0.05)
(Table I). In the Sβthal group, only five patients
were evaluated for sTfR levels, all of whom
showed extremely high values (Figure 1). Two
SS individuals had laboratory profiles compatible
with iron deficiency anemia: microcytic
hypochromic anemia, reduced levels of SI and
SF, high TIBC, transferrin saturation (TS) <15%
and a normal level of Hb A2. The sTfR
concentrations for these patients did not differ
from those observed in other members of the
same group. However, the receptor/ferritin ratio
was >500 in both cases, a finding compatible
with iron depletion.
2
 A significant inverse
correlation between sTfR levels and the HbF
concentration was seen in SS patients, but not in
the SC+CC group (Table III).
sTfR levels and spleen function. All patients
with sickle cell diseases presented some degree
of spleen function deficiency based on how much
above normal values (>2%) the pitted erythrocyte
percentage was.
12
 The degree of variability in
this parameter was considerable (Table II). No
correlation was observed between the number
of pitted erythrocytes and the sTfR values. To
determine whether an elevated RCF could have
resulted from a malfunction in spleen exocytosis
capacity, we examined the correlation between
the number of pitted erythrocytes and RCF levels.
A positive correlation was observed (p=0.051)
between these two variables in SS patients, but not
in SC or CC individuals (Table III).
DISCUSSION
We found a significant increase in sTfR
levels in all of the patients studied, with
significantly higher levels in the SS group than
in the SC+CC group. These findings agree with
those in the literature.
5,14-16
The transferrin receptor is a membrane
glycoprotein responsible for internalizing
transferrin in the erythrocyte cell. Following the
formation of a vesicle, fusion of the endosomes
and acidification, iron is released for heme
synthesis, while the receptor returns to the cell
membrane and the apotransferrin to the
TABLE 2 - Evaluation of spleen function - % of
erythrocytes with pits
Group n mean SD
(range)
N 28 0.66 0.54
(0 to 1.8)
SS 43 26.51 7.98
(5 to 41.8)
Sßthal 7 21.74 15.68
(2.9 to 44.6)
SC+CC 10 22.17 12.16
(5 to 47.2)
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plasma.
4,17
 The principal factors regulating the
density of these receptors in the cells are the
quantity of iron, stimulation by erythropoetin and
the cell cycle.
18
 The sTfR is found in human plasma
and appears be a truncated form of the tissue
receptor generated by a proteolytic mechanism
that is still not well understood.
17
 It has been
suggested that the serum concentration of sTfR
may be an accurate indicator of iron depletion,
especially in distinguishing between iron-
deprivation anemia and chronic disease
anemia.
19
 In situations where erythropoiesis is
threatened, such as in aplastic anemia, the sTfR
levels are significantly lower than in patients with
iron deficiency anemia, hemolytic anemia or in
normal individuals.
20
In hemoglobinopathy, an elevation in sTfR
levels may result from the high degree of
erythrocyte expansion found in this illness.
Corroborating this hypothesis is the demonstration
of an inverse relationship between sTfR levels and
the age of the patients, as well as between sTfR
levels and HbF rates.
5
 Serjeant et al
16
 studied the
possible determinants of HbF levels in SS patients
in Jamaica and found that HbF had no influence
on sTfR levels, although there was a tendency for
sTfR concentrations to decrease as the Hb level
increased. In our subjects, there was an inverse
correlation between the sTfR and HbF levels in
the SS, but not the SC+CC group. This negative
correlation in SS patients supports the hypothesis
that high HbF levels inhibit sickling and hemolysis,
thereby minimizing erythropoietic activity.
5
The results obtained in the present study
have confirmed those reported in the literature,
indicating that patients with sickle cell anemia
have some degree of spleen function deficiency.
7
Whilst there may be great variability in the pitted
erythrocyte counts in these cases, they are always
higher than in normal individuals.
12,21,22
 In none
TABLE 3 - Correlation between variables
Variables Group n Correlation coefficient (r) p value
sTfR x HbF SC+CC 9 0.4667 0.2054
SS 41 -0.4765 0.0016*
sTfR x PITS SC+CC 9 -0.2833 0.4600
SS 42 -0.0550 0.7292
sTfR x RCF SC+CC 9 0.3000 0.4328
SS 40 -0.1298 0.4248
RCF x PITS SC+CC 9 0.0546 0.8810
SS 41 0.3066 0.0512
sTfR x HbF SC+CC 9 0.4667 0.2054
SS 41 -0.4765 0.0016*
sTfR x HbF SS, RPI<2 11 -0.8767 0.0004*
SS, RPI>3 23 -0.2347 0.2810
RCF x SF SS 41 0.4774 0.0016*
SC+CC 10 -0.4128 0.2291
TS x RCF SS 41 0.3645 0.0191*
SC+CC 10 0.8182 0.0038
* statistically significant
HbF: fetal hemoglobin
RCF: red cell ferritin
TS: transferrin saturation
RPI: reticulocyte production index
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of our patients was there any spleen hyperactivity,
nor had any of them undergone splenectomy.
Our analysis therefore refers to sTfR behavior in
patients with hypoactive spleens in whom
erythropoietic activity was not exacerbated. In
these cases, the abnormally high sTfR values result
from chronic hemolysis and from erythropoietic
expansion at the level of the marrow with a
greater release of red cells into the circulation.
Crosby,
23
 commenting on hematopoiesis in the
human spleen, indicated that in diseases that
require a high reactive production of red blood
cells by the bone marrow, small clusters of
hematopoietic cells may be found in the spleen.
This possibility may be considered to make some
contribution to the elevation of sTfR levels in sickle
cell disease patients.
 In our study, high RCF levels were seen
in SS and Sβthal patients; patients with C
hemoglobinopathy had values approximating
those of normal individuals. The possible causes
of high RCF in hemoglobinopathy include greater
capture of iron by erythrocyte tissue, inadequate
utilization of iron in Hb synthesis, an increase in
apoferritin synthesis subsequent to greater release
of iron due to intracellular denaturation,
increased erythrocyte destruction and deficiency
in the process of exocytosis or “pitting” resulting
in the inefficient removal of excess ferritin by the
spleen.
8,9,13
We studied the latter aspect by quantifying
the number of pitted erythrocytes. Although the
correlation coefficient was not significant, its
value suggests a possible contribution of spleen
function deficiency to RCF accumulation in
patients with sickle cell anemia.
We conclude that patients with sickle cell
diseases show important alterations relevant to
sTfR behavior. In SS patients, the association
between sTfR and HbF confirms the contribution
of HbF to improving the hemolytic state by
minimizing the consequent reactive erythrocyte
expansion. RCF levels as an indicator of iron
accumulation have a limited value and need to
be analyzed together with other pertinent
laboratory parameters. Spleen function
deficiency apparently does not interfere with or
participate in alterations of iron metabolism,
although deficiencies from “pitting” could
contribute to a reduced ability to remove ferritin
from erythrocytes.
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RESUMO
Objetivo: Relacionar a função esplênica com os níveis do receptor solúvel da transferrina (sTfR) e com os valores da ferritina
intra-eritrocitária (RCF) em pacientes com doenças falciformes. Tipo de Estudo: Estudo prospectivo. Local: Hospital das
Clínicas da Faculdade de Ciências Médicas da UNICAMP, atendimento terciário. Participantes: 60 pacientes portadores de
doenças falciformes, na fase estável da doença, sem transfusão de sangue nos últimos 3 meses; 28 indivíduos normais, sem
sinais clínicos e laboratoriais de anemia. Variáveis estudadas: Determinação do ferro sérico, capacidade de ligação do ferro
à transferrina, ferritina sérica, RCFe sTfR. Avaliação da função esplênica: quantificação de hemácias com “pits”. Resultados:
Pacientes com anemia falciforme: os níveis de sTfR foram significativamente mais elevados do que nos indivíduos normais e com
Hb SC (p=0,0001); correlação inversa entre sTfR e Hb Fetal (p=0,0016); valores de RCF significativamente mais elevados  do
que nos indivíduos normais e pacientes SC (p=0,0001); correlação entre RCF e hemácias com “pits” (p=0,0512).Conclusões:
A associação entre sTfR e Hb Fetal confirma a contribuição da Hb Fetal na melhora do quadro hemolítico, o que,
conseqüentemente, minimiza a reativação da expansão eritróide. Os altos níveis de sTfR observados nos pacientes com doença
falciforme não estão relacionados com o grau de hipofunção esplênica. A deficiência do processo de exocitose exercido pelo
baço pode contribuir para o acúmulo de RCF nos pacientes com anemia falciforme.
